FierceBiotech 18. Dez. 2025 Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
FierceBiotech 18. Dez. 2025 Verge Genomics drops sole clinical candidate in return to AI drug discovery roots
FierceBiotech 18. Dez. 2025 Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success
FierceBiotech 18. Dez. 2025 After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3
FierceBiotech 18. Dez. 2025 Lindus Health and Quotient team up to create one-stop shop for early to mid-stage trials
FierceBiotech 17. Dez. 2025 Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road
FierceBiotech 17. Dez. 2025 Norgine gets in on Vir's hepatitis D program with €550 European licensing pact
FierceBiotech 17. Dez. 2025 Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay
FierceBiotech 17. Dez. 2025 Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst
FierceBiotech 17. Dez. 2025 Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team
FierceBiotech 17. Dez. 2025 Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B